Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Safety and efficacy of post transplant cyclophosphamide vs tacrolimus plus methotrexate for gvhd prophylaxis in myelofibrosis

View Full Paper
Ask AI
Bookmark
Share

Authors

CMCarolyn Mead‐HarveyKCKanishka Uttam ChandaniDQDiana Zamora Quintanilla

Discussion

Loading...

Member takes

Overview

Retrospective study finds similar chronic GVHD rates with post-transplant cyclophosphamide in myelofibrosis, indicating alternative viability.

Key Points

  • This research aims to compare the safety and efficacy of post-transplant cyclophosphamide and tacrolimus plus methotrexate for GVHD prophylaxis in myelofibrosis patients.
  • Retrospective study of patients with myelofibrosis undergoing allo-HCT from 2016 at Mayo Clinic.
  • Comparison of graft-versus-host disease rates, overall survival, and progression-free survival between PTCy and non-PTCy regimens.
  • Statistical analyses included Kaplan-Meier methods, Cox proportional hazards models, and competing risk models.
  • PTCy-treated patients showed similar rates of acute and moderate-severe chronic GVHD compared to non-PTCy regimens.
  • Engraftment was significantly delayed in the PTCy group for both platelets and neutrophils.
  • Median overall survival was 72.8 months for PTCy compared to 93.4 months for non-PTCy, without statistical significance.

Cite This Study

Mead‐Harvey et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d170https://doi.org/10.1182/blood-2025-6016
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Post-transplant cyclophosphamide based GVHD prophylaxis in HLA-matched related and unrelated donor hematopoietic cell transplantation in adults with hematologic malignancies undergoing myeloablative conditioning: A CIBMTR analysis of 8,272 participants2025
  2. 2Post-transplant cyclophosphamide vs tacrolimus/methotrexate: Improved GRFS, reduced NRM, and less severe GVHD in myeloablative HLA-matched allogeneic transplantation2025
  3. 3Post-transplant cyclophosphamide (PTCy) versus other graft-versus-host disease prophylaxis strategies in reduced intensity allogeneic stem cell transplantation from related and matched unrelated donors in patients with acute myeloid leukemia and myelodysplastic syndromes: A study from the french society of bone marrow transplantation (SFGM-TC) registry2025
  4. 4Post-transplant cyclophosphamide-based graft-verses-host disease (GVHD) prophylaxis is associated with a low incidence of fibrotic chronic GVHD after allogeneic hematopoietic cell transplantation across diverse donor types2025
  5. 5Post-transplant cyclophosphamide improves survival compared to antithymocyte globulin in HLA-mismatched unrelated donor stem cell transplantation2025 · 1 citations